The Manila Times

AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca’s Durvalumab in the Treatment of Metastatic Pancreatic …

AIM ImmunoTech Inc. (NYSE American: AIM) ('AIM” or the 'Company”) today announced milestones in the expected timeline for the ...

AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced an agreement with the PPD™ clinical research business of Thermo Fisher Scientific to design AIM’s anticipated Phase 3 ...
EurekAlert!

Study: ADRIATIC clinical trial results suggest durvalumab may offer a new path in small cell lung cancer care

MIAMI, FLORIDA (Jan. 9, 2026) – A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living with small cell lung cancer (SCLC). However, ...
ascopubs.org

A phase IIa clinical trial of first-line cyclical therapy alternating gemcitabine, cisplatin, and durvalumab with pemigatinib for advanced biliary tract cancers with FGFR2 ...

Transarterial chemoembolization (TACE) combined with camrelizumab and apatinib versus TACE alone in the treatment of unresectable hepatocellular carcinoma eligible for embolization: A multicenter, ...
Nasdaq

AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi ...

OCALA, Fla., Feb. 05, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported positive data in a year-end update from the ongoing Phase 2 clinical ...
Renal & Urology News

Durvalumab + Tremelimumab Associated With Improved DFS, Worse QoL in RCC

In this substudy of the phase 3 RAMPART trial, researchers compared quality-of-life measures among patients who received either active monitoring or durvalumab plus tremelimumab for resected RCC.
Oncology Nursing News

Early QOL Dip Seen With Adjuvant Durvalumab/Tremelimumab in RCC

Patients with resected renal cell carcinoma (RCC) receiving adjuvant durvalumab (Imfinzi) plus tremelimumab-actl (Imjudo) experienced early reductions in patient-reported quality of life (QoL), ...